Physician profile
Donna E Tudor
NPI 1467489500
$5,985.14
in general payments reported to CMS, 2019-2025
31 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,397 · 2022: $1,456 · 2023: $1,218 · 2024: $1,189 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.61 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.63 | 2021-2025 | |
| Novo Nordisk INC | $1,175.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $586.28 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $390.94 | 2021-2025 | Veozah |
| Lilly USA, LLC | $381.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $240.92 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.86 | 2021-2023 | |
| Amgen INC. | $214.85 | 2021-2024 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $141.01 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $105.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.45 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $99.06 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.11 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $91.52 | 2022-2025 | Rexulti |
| Abbott Laboratories | $82.09 | 2021-2024 | Freestyle Libre 2 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $68.85 | 2022 | |
| Amarin Pharma, INC. | $57.91 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.09 | 2021 | |
| Xeris Pharmaceuticals, INC. | $53.02 | 2023-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $52.11 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $46.49 | 2021-2022 | |
| Dexcom, INC. | $40.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.54 | 2021 | |
| Exact Sciences Corporation | $29.40 | 2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $29.30 | 2021 | |
| Gilead Sciences, INC. | $23.91 | 2022 | |
| Lundbeck LLC | $21.50 | 2024 | Vyepti |
| Corcept Therapeutics | $19.86 | 2024 | Korlym |
| Mylan Specialty L.P. | $14.83 | 2022 | |
| Eisai INC. | $11.97 | 2021 | |
| Sumitomo Pharma America, INC. | $9.83 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Tudor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.